Healthpoint

Unapproved marketing of pressure ulcer drug brings settlement worth up to $48 million

Unapproved marketing of pressure ulcer drug brings settlement worth up to $48 million

By

The unapproved bed sore drug Xenaderm, which was marketed to nursing homes as "Medicaid reimbursed," is the source of a settlement that could reach $48 million for Healthpoint Ltd. and DFB Pharmaceuticals.